Shift in Biosimilar Commercial Landscape Essential for Sector Sustainability, Expert Says

Why It Matters

Without a viable commercial model, biosimilars cannot scale, limiting cost savings for payers and patients while threatening global biologic supply security.

Key Takeaways

• Biosimilar development costs ~100× generic drug costs.
• US biosimilar makers earn <10% of list price revenue.
• 90% of upcoming biologic patents lack biosimilar pipelines.
• ICH guideline aims to cut comparative clinical study requirements.
• Red Tape Elimination Act would auto‑grant interchangeability.

Pulse Analysis

The biosimilar sector sits at a crossroads where scientific feasibility outpaces commercial viability. Development budgets can be a hundred times those of traditional small‑molecule generics, yet U.S. market dynamics leave biosimilar manufacturers with under ten percent of the list‑price revenue that brand‑name biologics command. This cost‑revenue mismatch discourages investment, creating a looming void as patents for a majority of high‑value biologics expire. Payers and patients stand to lose substantial savings unless the pricing architecture is rebalanced and incentives realigned.

Regulatory progress offers a pathway to lower barriers. After three decades of collaboration, the International Council for Harmonisation (ICH) released its first biosimilar guideline, streamlining requirements by reducing reliance on extensive comparative clinical efficacy studies. In the United States, the FDA’s recent guidance eases data burdens, and bipartisan proposals such as the Red Tape Elimination Act aim to make every approved biosimilar automatically interchangeable. Parallel efforts to modernize the Biologics Price Competition and Innovation Act and secure biosimilar user‑fee funding could further stabilize the approval pipeline, encouraging manufacturers to commit capital.

Globally, emerging markets are reshaping the supply landscape. Brazil leads in South America, while Korea, India, and China accelerate domestic production, though many still grapple with cGMP compliance. These regions present growth opportunities that can offset U.S. on‑shoring challenges and diversify risk. As governments tighten price controls and prioritize supply‑chain security, transparent pricing and harmonized regulations become critical levers for unlocking the biosimilar promise and delivering affordable biologic therapies worldwide.